Loading...
•
Jun 30, 2020
Arvinas Q2 2020 Earnings Report
Reported financial results for the second quarter ended June 30, 2020 and provided a corporate update.
Key Takeaways
Arvinas reported its Q2 2020 financial results, highlighted by revenue of $5.7 million and a net loss of $25.2 million. The company's cash, cash equivalents, and marketable securities totaled $242.7 million as of June 30, 2020, expected to fund operations into 2022.
Presented early efficacy and updated safety data for ARV-110 at ASCO 2020, showing an acceptable safety profile and early signs of clinical efficacy in a heavily pretreated patient population.
Enhanced the Board of Directors with the appointments of Linda Bain and Wendy Dixon, Ph.D.
Expects to provide an update from its Phase 1/2 trial for ARV-110 in the fourth quarter of 2020.
Expects to share Phase 1 dose escalation clinical data for ARV-471 in the fourth quarter of 2020.
Revenue by Segment
Forward Guidance
Based on its current operating plan, Arvinas expects its cash, cash equivalents, and marketable securities will be sufficient to fund its planned operating expenses and capital expenditures into 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...